CA1339044C - Insulin derivatives, the use thereof, and a pharmaceutical composition containing them - Google Patents

Insulin derivatives, the use thereof, and a pharmaceutical composition containing them

Info

Publication number
CA1339044C
CA1339044C CA000614539A CA614539A CA1339044C CA 1339044 C CA1339044 C CA 1339044C CA 000614539 A CA000614539 A CA 000614539A CA 614539 A CA614539 A CA 614539A CA 1339044 C CA1339044 C CA 1339044C
Authority
CA
Canada
Prior art keywords
formula
insulin
physiologically tolerated
tolerated salts
insulin derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000614539A
Other languages
French (fr)
Inventor
Michael Dorschug
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6366698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA1339044(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of CA1339044C publication Critical patent/CA1339044C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

New insulin derivatives, the use thereof, and a pharmaceutical composition containing them New insulin derivatives of the formula II with an iso-electric point between 5 and 8.5, with improved stability in weakly acid aqueous medium and with a special action profile, and the physiologically tolerated salts of these insulin derivatives, for the treatment of diabetes mellitus; formula II is:

Description

A Description New insulin derivatives, the u~e thereof, and a phaImaceutical composition containing them As is known, insulin and insulin derivatives are required in considerable quantities for the treatment of the disease diabetes mellitus, and some of them are also produced on an industrial scale. Despite the considerable number of insulin compositions and modifications with different action profiles which are already in existence, there is still a need, because of the variety of organ-isms with their inter- and intraindividual variations, for other insulin products which in turn have other properties and action characteristic6.

Insulin derivatives with a delayed action are described, for example, in EP-B 132,769 (published 13 Feb 85) and EP-B 132,770 (published 13 Feb 85). These are specifically derivatives with a basic modification in position B31 of the insulin B chain, of the following formula I:

H-Gly~ I ~-c ~ n ~ Asn-~

¦ (I) S , .

R -Val B-d~n-His R -~R

in which Rl denotes H or H-Phe, R30 represents the residue of a neutral, genetically encodable L-amino acid, and R31 represents a physiologically acceptable organic group which is ba~ic in nature and has up to 50 carbon atoms, 133904~
in whose structure 0 to 3 ~-amino acids are involved and whose terminal carboxyl group which i8 present where appropriate can be free, in the form of an ester func-tionality, an amide functionality, a lactone or reduced to CH20H.

Characteristic of these insulin derivatives is an iso-electric point between 5.8 and 8.5 (measured by iso-electric focusing). The fact that the isoelectric point i8 shifted from the isoelectric point of unmodified natural insulin or proinsulin (at pH = 5.4) into the neutral range derives from the additional positive charge(s) located on the surface of the molecule as a result of the basic modification. This makes these insulin derivatives with a basic modification less soluble in the neutral range than, say, natural insulin or proinsulin, which are normally dissolved in the neutral range.

The delaying or depot action of the insulin derivatives with a basic modification, of the formula I, derives from their sparing solubility at the isoelectric point.
According to the two abovementioned publications, the redissolution of the insulin derivatives under physio-logical conditions is achieved by elimination of the additional basic groups, which is brought about, depend-ing on the derivative, by trypsin or trypsin-like and/or carboxypeptidase B or carboxypeptidase B-like and/or esterase activity. The eliminated groups are in each case either purely physiological metabolites or else easily metabolized physiologically acceptable substances.
\

30 The abovementioned depot principle resulting from basic modification of the insulin has also been further util-ized by the provision and corresponding use of other insulin derivatives with basic modifications, mainly within the A and B chains; cf. for example EP-A 0,194,864 ~- 35 (published 12 Nov 86) and EP-A 0,254,516 (published 27 - Jan 88).
3 13390~

In the insulin derivatives specified in EP-A 0,194,864, a basic amino acid is incorporated in the B27 position and/or a neutral amino acid is located at positions A4, A17, B13 and/or B21; in addition, the C-terminal carboxyl group of the B chain is blocked by an amide or ester residue.

The insulin derivatives specified in EP-A 0,254,516 are very similar to those specified in the abovementioned EP-A; however, in this case, with the aim of increasing the stability of the relevant pharmaceutical compositions at the weakly acid pH values, the amino acid Asn in position A21 can also be replaced by other amino acids which are more stable in acid medium, such as, for example, Asp. As is known, Asn (= asparagine) differs from Asp (= aspartic acid) by the blocking of one of the two carboxyl groups by the amide group:

COOH COOH
H2N - C - H HzN - C - H

~ONH2 COOH
asparagine a~partic acid Rapid-acting insulin derivatives are said to result from yet another modification of the insulin molecule in the A and B chain, in particular by replacing the amino acid His, which is responsible for the formation of a complex with zinc - and thus for a certain delaying action, in the B10 position by other appropriate amino acids; cf.
EP-A 0,214,826 (published 18 Nar 87).

All the insulin derivatives specified in the 3 last-mentioned publications are mainly modified within the A
and B chains; they are prepared by genetic engineering routes.

In the attempt to increase the stability in acid medium of the insulin derivatives with a ba~ic modification on _ _ 4 _ 1339044 the C-terminal end of the B chain as specified in the European Patents EP-B 0,132,769 and EP-B 0,132,770 mentioned in the introduction, and, where appropriate, also to alter the action profile thereof, it has now been 5 found that this object is achieved in an advantageous manner by replacing Asn~l by other genetically encodable amino acids which contain no amide group and, where appropriate, by replacing HisB10 by other genetically encodable amino acids.

Hence the invention relates to insulin derivatives of the formula II
Al S- S A21 H-Gly A-c~n I f R
S S
s R -Val B-ch~n-X R -R
in which Rl denotes H or H-Phe, R2 denotes a genetically encodable L-amino acid which contains no amide group, R30 represents the residue of a neutral genetically encodable L-amino acid, R3l represents a physiologically acceptable organic group which is basic in nature and has up to 50 carbon atoms, in whose structure 0 to 3 ~-amino acids are involved and whose terminal carboxyl group which is present where appropriate can be free, in the form of an ester functionality, an amide func-tionality, a lactone or reduced to CH2OH, and X represents a genetically encodable L-amino acid, having an isoelectric point between 5 and 8.5, and the physiologically tolerated salts thereof.

The new insulin derivatives and the physiologically tolerated salts thereof are stable at the weakly acid pH
values of appropriate pharmaceutical compositions even for exten~ periods and have - especially when HisBl has also been replaced by other amino acids - an altered (shorter) action profile compared with the known -unaltered - insulin derivatives with a basic modification of the formula I indicated in the introduction.

Rl in formula II is preferably H-Phe.

Genetically encodable L-amino acids contAining no amide group - for R2 _ are Gly, Ala, Ser, Thr, Val, Leu, Ile, Asp, Glu, Cys, Met, Arg, Lys, His, Tyr, Phe, Trp, Pro;
Gly, Ala, Ser, Thr, Asp and Glu are preferred, especially Asp.

Neutral genetically encodable L-amino acids - for R30 _ are Gly, Ala, Ser, Thr, Val, Leu, Ile, Asn, Gln, Cys, Met, Tyr, Phe and Pro; Ala, Thr and Ser are preferred.

R3l is a physiologically acceptable organic group which i8 basic in nature and has up to 50 carbon atoms and in whose structure 0 - 30 ~-amino acids are involved. When no ~-amino acids are involved in the structure of R3l, examples of suitable basic groups for this residue are the following:
amino-(C2-C6)-alkoxy, (Cl4)-alkylamino-(C2-C6)-alkoxy, di-(Cl-C4)-alkylamino-(C2-C6)-alkoxy, tri-(Cl-C4)-ammonio-(C2-C6)-alkoxy, amino-(C2-C6)-alkylamino, t(Cl-C4)-alkyl-amino]-(C2-C6)-alkylamino, di-(Cl-C4)-alkylamino-(C2-C6)-alkylamino or [tri-(Cl-C4)-alkylamino]-(C2-C6)-alkylamino, especially -O-[CH2]p, NR2, [-O-]cH2p-N~R3, -NH-[CH2]p-NR2 or -NH-[CH2]p-N~R3 in which p is 2 to 6, and R is identical or different and represents hydrogen or (C1-C4)-alkyl.

When up to 3 ~-amino acids are involved in the structure of R3l, these are primarily neutral or basic naturally occurring L-amino acids and/or the D-amino acids 13~909~

corresponding thereto. Neutral naturally occurring amino acids are, in particular, Gly, Ala, Ser, Thr, Val, Leu, Ile, Asn, Gln, Cys, Met, Tyr, Phe, Pro and Hyp. Basic naturally occurring amino acids are, in particular, Arg, Lys, Hyl, Orn, Cit and His. If only neutral ~-amino acids are involved, the terminal carboxyl group thereof cannot be free - in order for R3' to be basic in nature; on the contrary, the carboxyl group must in this case be amidat-ed or esterified with a basic group, suiitable basic groups for this being, for example, the abovementioned basic groups - in the case where no ~-amino acids are involved in the structure of R31. Of course, these basic ester or amide groups can also block the carboxyl group of basic ~-amino acids. Also possible and suitable for blocking the carboxyl group of the basic ~-amino acids are - if the blocking is desired - neutral ester or amide groups such as, for example, (C1-C6)-alkoxy, (C3-C6)-cycloalkyloxy, NH2, (C1-C6)-alkylamino or di-(C1-C6)-alkylamino.

Of course, the terminal carboxyl group can be in the form of a lactone only if the terminal amino acid is a hydr-oxyamino acid.

Moreover, the terminal carboxyl group can also be reduced to CH20H.

R31 is preferably composed of 1, 2 or 3 of the above-mentioned basic naturally occurring amino acids; R31 is particularly preferably Arg-OH or Arg-Arg-OH.

Suitable genetically encodable L-amino acids - for X -are the same amino acids as for R2, but the genetically encodable L-amino acids which contain an amide group -which are Asn and Gln - are also possible in this case;
the latter - Asn and Gln - are in fact preferred in this case. If Asn or Gln is located in position B10, the amide group is at least stable in weakly acid medium (in contrast to Asn or Gln in position A21).

13390~4 The sequences (A1 - A20) and (Bl - B9, B11 - B29) are preferably the sequences of human, porcine or bovine insulin, especially the sequences of human insulin.

Examples of insulin derivatives of the formula II are:

5 Asp -Human insulin-ArgB31 OH
GlUA21_ ~.
GlyA21_ SerA21_ ThrA21_ AlaA21_ ~, AspA2l-Human inSulin-Args3l-Args32 OH
GlUA21 "
GlyA21_ ~
SerA21_ "
ThrA21 "
AlaA21_ "

Asp~2l-AsnBl0-Human insulin-ArgB3l-OH
GlUA21_ "
GlyA21_ serA21_ "
ThrA21_ "
AlaA21_ ~

AspA2l-AsnBl0-Human insulin-ArgB3l-ArgB32-OH
GlUA21_ "
GlyA21_ "
SerA21_ "
ThrAZl "
AlaA21_ "

The insulin derivatives of the formula II are prepared mainly by a genetic manipulation by means of site-directed mutagenesis using stA~Ard methods.

For this purpose, a gene structure coding for the desired - insulin derivative of the formula II is constructed and its expression is brought about in a host cell - prefer-ably in a bacterium such as E. coli or a yeast, in particular Saccharomyces cerevisiae - and - if the gene structure codes for a fusion protein - the insulinderiva-tive of the formula II is liberated from the fusion protein; analogous methods are described, for example, in EP-A 0,211,299 (published 25 Feb 87), EP-A 0,227,938 (published 27 ~ay 87), EP-A 0,229,998 (published 14 June 87), EP-A 0,286,956 (published 12 Oct 88) and German Patent Application P 38 21 159.9 dated June 23, 1988 (HOE 88/F 158).

After cell disruption, the fusion protein portion is eliminated either chemically using cyanogen halide or enzymatically using lysostaphin - cf. DE-A 3,739,347 (published 22 May 89).

The insulin precursor is then sub~ected to oxidative sulfitolysis by the method described, for example, by R.C. Marshall and A.S. Inglis in "Practical Protein Chemistry - A ~An~hook~ (edited by A. Darbre) 1986, pages 49 - 53, and subsequently renatured in the presence of a thiol with the formation of the correct disulfide bridges, for example by the method described by G.H.
Dixon and A.C. Wardlow in Nature (1960), pages 721 - 724.

The C peptide is removed by cleavage with trypsin - for example by the method of Kemmler et al., J.B.C. (1971), pages 6786 - 6791, and the insulin derivative of the formula II is purified by known techniques such as chromatography - cf., for example, EP-A-0,305,760 (published 14 Apr 89) - and crystallization.

The insulin derivatives of the formula II with R2 = Asp and X = His are eYre~iently prepared by hydrolysis of the known insulin derivatives which have a basic modification and the formula I in aqueous acidic medium (because only the amide group of the asparagine in position A21 must be hydrolyzed in this case), preferably at pH values between . ~, about 2 and about 4, in particular of about 2.5, and at temperatures of about 0 to about 40C, preferably at room temperature.

The insulin derivatives of the formula II, according to the invention, and/or the physiologically tolerated salts thereof (such as, for example, the alkali metal or ammonium salts) are mainly used as active substances for a pharmaceutical composition for the treatment of diabetes mellitus.

The pharmaceutical composition is preferably a solution or suspension for injection; it contains at least one insulin derivative of the formula II and/or at least one of the physiologically tolerated salts thereof in dis-solved, amorphous and/or crystalline - preferably in dissolved - form.

The composition preferably has a pH between about 2.5 and 8.5, in particular between about 4.0 and 8.5, and con-tains a suitable tonicity agent, a suitable preservative and, where appropriate, a suitable buffer, as well as preferably a certain zinc ion concentration, all, of course, in sterile aqueous solution. All the ingredients of the composition apart from the active substance form the composition vehicle.

Examples of suitable tonicity agents are glycerol, glucose, mannitol, NaCl, and calcium or magnesium com-pounds such as CaCl2, MgCl2 etc.

The choice of the tonicity agent and/or preservative influences the solubility of the in~ulin derivative or the physiologically tolerated salt thereof at the weakly acid pH values.

Examples of suitable preservatives are phenol, m-cresol, benzyl alcohol and/or p-hydroxybenzoic esters.

Examples of buffer substances which can be used, in particular for adjusting a pH between about 4.0 and 8.5, are sodium acetate, sodium citrate, sodium phosphate etc.
Otherwise, also suitable for adjusting the pH are physio-logically acceptable dilute acids (typically HCl) oralkalis (typically NaOH).

When the composition contains zinc a content of 1 ~g to 2 mg, in particular from 5 ~g to 200 ~g, of zinc/ml is preferred.

In order to vary the action profile of the composition according to the invention it is also possible to admix unmodified insulin, preferably bovine, porcine or human insulin, in particular human insulin.

Preferred concentrations of active substance are those corresponding to about 1-1500, also preferably about 5-1000, and in particular about 40-400, international units/ml.

The invention is now explained in detail by the examples which follow.

A) Preparation bY genetic man irll~tion Example 1 Construction of a plasmid for the preparation of Gly (A21)-human insulin Arg (B31-OH) The plasmid pSW3 has been described in German Patent Application P 38 21 159.9 (HOE 88/F 158). The plasmid DNA
is reacted with the restriction enzymes PvuII and SalI
and subsequently treated with bovine alkaline phosphatase. The two resulting fragments are separated by gel electrophoresis, and the large fragment is isolated.
This fragment is linked in a T4 DNA ligase reaction with the following synthetic DNA sequence:

13~9044 5'- CTG GAA AAC TAC TGT GGT TGA TAG
GAC CTT TTG ATG ACA CCA ACT ATC AGCT - 5' Competent E. coli W3110 cells are transformed with the ligation mixture. The transformation mixture i8 plated out on NA plates which contain 20 ~g of Ap (=Ampicillin)/
ml and incubated at 37C overnight. An overnight culture is obtained from single colonies, and plasmid DNA is ob-tAine~ from this. This DNA is characterized by means of restriction analysis and DNA sequence analysis. Correct plasmids which encode the modified A chain are called pIK100. Expression is carried out in analogy to Example 3 of the abovementioned German Patent Application P 38 21 159.9. The modified mono-Arg-insulin is likewise prepared in analogy to the preparation of the unmodified mono-Arg-insulin described in this German Patent Application.

Example 2 Construction of a plasmid for the preparation of Ser(A21)-human insulin (Arg B31-OH) The construction corresponds to the route described in the above example. The synthetic DNA sequence is, however, modified as follows:

5' - CTG GAA AAC TAC TGT TCA TGA TAG
GAC CTT TTG ATG ACA AGT ACT ATC AGCT - 5' The plasmid pIK110 which has an additional BspHI recog-nition sequence is obtAine~.

Esample 3 Construction of a plasmid for the preparation of Gly(A21)-Asn(B10)-human insulin Arg(B31-OH) 133904~

DNA from the plasmid pIR100 is cleaved with the restriction enzymes HpaI and DraIII and treated with bovine alkaline phosphatase. The two resulting fragments are separated by gel electrophoresis, and the larger of the two fragments is isolated. The fragment is ligated with the synthetic DNA sequence 5' - AAC CAA CAC TTG TGT GGT TCT AAC TTG
TTG GTT GTG AAC ACA CCA AGA TTG - 5' and competent E. coli W3110 cells are transformed with the ligation mixture. Further characterization of the resulting plasmid pIR101 is carried out as described in Example 1.

Example 4 Construction of a plasmid for the preparation of Ser(A21)-Asn(B10)-human insulin The construction corresponds to the cloning described in Example 3, but starting from DNA from the plasmid pIR110.
The newly constructed plasmid is called pIR111.

Example 5 Construction of an expression plasmid for monkey proinsulin Monkey proinsulin differs from human proinsulin merely by replacement of a single amino acid in the C peptide (B37-Pro in place of Leu in this position of human proinsulin).

The plasmid pSW3 is opened with HpaI and SalI and the remaining plasmid DNA is isolated. The DraIII-SalI monkey proinsulin fragment is isolated from the plasmid pK50 described in EP-A0,229,998. The two fragments are linked to the synthetic DNA fragment 13390~

5' - AAC CAG CAC CTG TGC GGT TCT CAC CTA
TTG GTC GTG GAC ACG CCA AGA GTG - 5' in a T4 DNA ligase reaction. The plasmid pSW2 is obt~ P~l, and its DNA is used hereinafter as starting material for the constructions of the expression plasmids encoding the di-Arg-human insulin derivatives.

E~ample 6 Construction of a plasmid for the preparation of Gly(A21)-human insulin Arg(B31)-Arg(B32)-OH

DNA of the plasmid pSW2 is cleaved with PvuII and SalI in accordance with Example 1 and ligated with the synthetic DNA from Example l; the result is the plasmid pSW21.

Esample 7 Construction of a plasmid for the preparation of Ser(A21)-human insulin-Arg(B31)-Arg(B32)-OH

The plasmid pSW22 is constructed starting from pSW2 DNA
in analogy to Example 2.

~cample 8 Construction of a plasmid for the preparation of Gly(A21)-Asn(B10)-human insulin-Arg(B31)-Arg(B32)-OH

The plasmid pSW23 is constructed starting from pSW21 DNA
in analogy to Example 3.

The following sequence is used as synthetic DNA sequence for this:

5' - AAC CAA CAC TTG TGT GGT TCT AAC CTA
TTG GTT GTG AAC ACA CAA AGA TTG - 5' - 14 - 1~39044 -~xample 9 Construction of a plasmid for the preparation of Ser(A21)-Asn(B10)-human insulin-B31(Arg)-B32(Arg)-OH

The plasmid pSW24 is constructed starting from pSW22 DNA
in analogy to Example 4 using the synthetic DNA ~equence described in Example 8.

B) Preparation of Asp~2l-human insulin-Ar ~l-Ar ~2-oH
from human insulin-Ar~31-Ar~32-OH by hYdrolysis 1 g of human insulin-ArgB3l-ArgB32-OH is suspended in 100 ml of H20. The pH is adjusted to 2.5 by addition of HCl, and the solution is left at 37C. After one week about one half of the material has been converted into AspA21-human insulin-ArgB31-ArgB32-OH. The product is separated from the starting material in a manner known per se on an anion exchanger, is precipitated from the eluate and is crystallized in a buffer which contains 10.5 g of citric acid, 1 g of phenol and 5 ml of a 1 ~ strength zinc chloride solution per liter with a protein concentration of 5 g/l at pH 6Ø The yield is 390 mg of AspA21-human inSulin-ArgB3l-Args32 C) PreParation of an in~ection solution The insulin derivative from B is dissolved at a con-centration of 1.4 mg/ml in a sterile vehicle solution of the following composition (per ml):
18 mg of glycerol, 10 mg of benzyl alcohol, 80 ~g of Zn , pH 4Ø

D) Action ~rofile of an AspA2l-human insulin-Ar ~l-Ar ~2-OH comPosition in dogs by comparison with human in-sulin-ArgB3l-ArgB32-OH and basal H insulin Hoechst~R~ = an NPH (neutral protamine Hagedorn) composition cont~ ng about 10 ~g of Zn2+.

Product Blood glucose as a % of the initial level in hours (h) 1 h 2 h 3 h 5 h 7h According AspA21-human to the insulin invention ArgB3l_Arg~32 OH 99 62 51 75 98 Human insulin ArgB31-Arg~32-OH 77 52 64 85 98 Comparison Basal H insulin Hoechst(R) 71 49 S9 83 100 This example shows that AspA21-human insulin-ArgB31-Arg~32-OH has the same advantageous basal profile as human insulin-Arg~31-ArgB32-OH- In addition, AspA21-human insulin-ArgB31-Arg~32-OH has the advantageous property that the compound is stable for a long time under the chosen conditions.

Claims (18)

1. An insulin derivative of the formula II

(II) R1 denotes H or H-Phe, R2 denotes a genetically encodable L-amino acid which contains no amide group, R30 represents the residue of a neutral genetically encodable L-amino acid, R31 represents a physiologically acceptable organic group which is basic in nature and has up to 50 carbon atoms, in whose structure 1 to 3 .alpha.-amino acids are involved and whose terminal carboxyl group which is present where appropriate can be free, in the form of an ester functionality, an amide functionality, a lactone or reduced to CH2OH, and X represents a genetically encodable L-amino acid, which has an isoelectric point between 5 and 8.5, and the physiologically tolerated salts thereof.
2. An insulin derivative and the physiologically tolerated salts thereof as claimed in claim 1, wherein R1 in formula II represents H-Phe.
3. An insulin derivative and the physiologically tolerated salts thereof as claimed in claim 1, wherein R2 in formula II represents Gly, Ala, Ser, Thr, Asp or Glu.
4. An insulin derivative and the physiologically tolerated salts thereof claimed in claim 1, wherein R2 in formula II
represents Asp.
5. An insulin derivative and the physiologically tolerated salts thereof as claimed in claim 1, wherein R30 in formula II represents Ala, Thr or Ser.
6. An insulin derivative and the physiologically tolerated salts thereof as claimed in claim 1, wherein R31 in formula II represents Arg-OH or Arg-Arg-OH.
7. An insulin derivative and the physiologically tolerated salts thereof as claimed in claim 1, wherein X in formula II
denotes Asn or Gln.
8. An insulin derivative and the physiologically tolerated salts thereof as claimed in claim 1, wherein the sequences (A1 to A20) and (B1 to B9, B11 to B29) in formula II are the sequences of human, porcine or bovine insulin.
9. An insulin derivative and the physiologically tolerated salts thereof as claimed in claim 8, wherein the sequences (A1 to A20) and (B1 to B9, B11 to B29) in formula II are the sequences of human insulin.
10. The use of the insulin derivatives and the physiologically tolerated salts thereof as claimed in any one of claims 1 to 9 as active substances for pharmaceutical compositions for the treatment of diabetes mellitus.
11. A pharmaceutical composition which contains an effective amount of at least one insulin derivative of the formula II and/or at least one of the physiologically tolerated salts thereof as claimed in any one of claims 1 to 9 in dissolved, amorphous and/or crystalline form, and a pharmaceutically acceptable vehicle.
12. A pharmaceutical composition which contains an effective amount of at least one insulin derivative of the formula II and/or at least one of the physiologically tolerated salts thereof as claimed in any one of claims 1 to 9 in dissolved form, and a pharmaceutically acceptable vehicle.
13. A pharmaceutical composition which contains an effective amount of at least one insulin derivative of the formula II and/or at least one of the physiologically tolerated salts thereof as claimed in any one of claims 1 to 9 in dissolved, amorphous and/or crystalline form and which additionally contains 1 µg to 2 mg of zinc/ml.
14. A pharmaceutical composition which contains an effective amount of at least one insulin derivative of the formula II and/or at least one of the physiologically tolerated salts thereof as claimed in any one of claims 1 to 9 in dissolved form and which additionally contains 5 µg to 200 µg of zinc/ml.
15. A pharmaceutical composition which contains an effective amount of at least one insulin derivative of the formula II and/or at least one of the physiologically tolerated salts thereof as claimed in any one of claims 1 to 9 in dissolved, amorphous and/or crystalline form and which additionally contains unmodified insulin.
16. A pharmaceutical composition which contains an effective amount of at least one insulin derivative of the formula II and/or at least one of the physiologically tolerated salts thereof as claimed in any one of claims 1 to 9 in dissolved form and which additionally contains unmodified human insulin.
17. A pharmaceutical composition which contains an effective amount of at least one insulin derivative of the formula II and/or at least one of the physiologically tolerated salts thereof as claimed in any one of claims 1 to 9 in dissolved, amorphous and/or crystalline form and which additionally contains 1 µg to 2 mg of zinc/ml, and unmodified insulin.
18. A pharmaceutical composition which contains an effective amount of at least one insulin derivative of the formula II and/or at least one of the physiologically tolerated salts thereof as claimed in any one of claims 1 to 9 in dissolved form and which additionally contains 5 to 200 µg of zinc/ml, and unmodified human insulin.
CA000614539A 1988-11-08 1989-09-29 Insulin derivatives, the use thereof, and a pharmaceutical composition containing them Expired - Lifetime CA1339044C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3837825A DE3837825A1 (en) 1988-11-08 1988-11-08 NEW INSULIN DERIVATIVES, THEIR USE AND A PHARMACEUTICAL PREPARATION CONTAINING THEM
DEP3837825.6 1988-11-08

Publications (1)

Publication Number Publication Date
CA1339044C true CA1339044C (en) 1997-04-01

Family

ID=6366698

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000614539A Expired - Lifetime CA1339044C (en) 1988-11-08 1989-09-29 Insulin derivatives, the use thereof, and a pharmaceutical composition containing them

Country Status (21)

Country Link
US (2) US5656722A (en)
EP (1) EP0368187B1 (en)
JP (1) JP2680145B2 (en)
KR (1) KR0158197B1 (en)
AT (1) ATE93868T1 (en)
AU (1) AU621680B2 (en)
CA (1) CA1339044C (en)
DE (3) DE3837825A1 (en)
DK (1) DK173196B1 (en)
ES (1) ES2059676T4 (en)
FI (1) FI100185B (en)
HU (2) HU213018B (en)
IE (1) IE63338B1 (en)
IL (1) IL92222A (en)
LU (1) LU90614I2 (en)
NL (1) NL300019I2 (en)
NO (2) NO177963C (en)
NZ (1) NZ231272A (en)
PH (1) PH30695A (en)
PT (1) PT92220B (en)
ZA (1) ZA898456B (en)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59208181D1 (en) * 1991-12-18 1997-04-17 Hoechst Ag Process for obtaining insulin-containing solutions
DK0622376T3 (en) * 1993-04-27 2001-11-12 Hoechst Ag Amorphous monospheric forms of insulin derivatives
DE19512484A1 (en) 1995-04-04 1996-10-17 Bayer Ag Carbohydrate modified cytostatics
DK0821006T3 (en) 1996-07-26 2004-08-16 Aventis Pharma Gmbh Insulin derivatives with increased zinc binding
DE19652713C2 (en) * 1996-12-18 2001-11-22 Aventis Pharma Gmbh Process for the purification of insulin and insulin derivatives by chromatography on a strongly acidic cation exchanger
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
SV1998000125A (en) * 1997-10-24 1999-05-24 Lilly Co Eli INSOLUBLE INSULIN COMPOSITIONS REF. X-11232
DE19825447A1 (en) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh New insulin analogues with increased zinc formation
DE19838097A1 (en) 1998-08-24 2000-03-02 Hoechst Marion Roussel De Gmbh Process for the chromatographic purification of insulins
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
EP1265630B1 (en) * 2000-03-24 2006-06-07 Genentech, Inc. Use of insulin for the treatment of cartilagenous disorders
US7316999B2 (en) 2000-06-02 2008-01-08 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
DE10114178A1 (en) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinc-free and low-zinc insulin preparations with improved stability
FR2822834B1 (en) * 2001-04-02 2005-02-25 Flamel Tech Sa COLLOIDAL SUSPENSION OF NANOPARTICLES BASED ON AMPHIPHILIC COPOLYMERS FOR VECTORIZATION OF ACTIVE INGREDIENTS AND THEIR METHOD OF PREPARATION
CA2452044A1 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
JP4563675B2 (en) 2001-10-12 2010-10-13 ハイ・ポイント・ファーマスーティカルズ、エルエルシー Substituted piperidines and their use for the treatment of histamine H3 receptor related diseases
CA2463803A1 (en) * 2001-10-19 2003-05-01 Eli Lilly And Company Biphasic mixtures of glp-1 and insulin
HUP0700126A2 (en) * 2001-12-20 2007-06-28 Lilly Co Eli Insulin molecule having protracted time action
US7774816B2 (en) * 2002-04-23 2010-08-10 Rovi Technologies Corporation Conflict manager for a video recorder
DE10227232A1 (en) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Sour insulin preparations with improved stability
FR2843117B1 (en) * 2002-07-30 2004-10-15 Flamel Tech Sa POLYAMINOACIDS FUNCTIONALIZED BY AT LEAST ONE HYDROPHOBIC GROUP AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
ATE482747T1 (en) 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc NEW AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USES
CA2518776A1 (en) * 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
FR2860516B1 (en) * 2003-10-03 2006-01-13 Flamel Tech Sa TELECHELIC HOMOPOLYAMINOACIDES FUNCTIONALIZED BY HYDROPHOBIC GROUPS AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
HUE043210T2 (en) 2003-11-20 2019-08-28 Novo Nordisk As Peptide formulations containing propylene glycol which are optimal for the preparation of injection devices
FR2862536B1 (en) * 2003-11-21 2007-11-23 Flamel Tech Sa PHARMACEUTICAL FORMULATIONS FOR THE PROLONGED DELIVERY OF ACTIVE (S) PRINCIPLE (S) AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
FR2873040B1 (en) * 2004-07-19 2007-11-30 Flamel Technologies Sa COLLOIDAL FORMULATION OF LONG-ACTING INSULIN AND ITS PREPARATION
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US8501739B2 (en) 2005-07-04 2013-08-06 High Point Pharmaceuticals, Llc Medicaments
WO2007015805A1 (en) 2005-07-20 2007-02-08 Eli Lilly And Company 1-amino linked compounds
SI1951658T1 (en) 2005-11-17 2012-11-30 Lilly Co Eli Glucagon receptor antagonists, preparation and therapeutic uses
FR2896164B1 (en) * 2006-01-18 2008-07-04 Flamel Technologies Sa COLLOIDAL FORMULATION OF LONG-ACTING INSULIN AND ITS PREPARATION
US20090054305A1 (en) 2006-03-15 2009-02-26 Novo Nordisk A/S Mixtures of Amylin and Insulin
ES2388681T3 (en) 2006-03-28 2012-10-17 High Point Pharmaceuticals, Llc Benzothiazoles with histamine H3 receptor activity
CA2649111C (en) 2006-04-24 2013-09-10 Eli Lilly And Company Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
AU2007267197B2 (en) 2006-05-29 2011-12-01 High Point Pharmaceuticals, Llc 3- (1, 3-Benzodioxol-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine H3 receptor antagonist
DE102006031962A1 (en) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidated insulin glargine
DE102006031955A1 (en) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Process for the preparation of dibasic B chain end insulin analogs
US7417517B2 (en) * 2006-07-13 2008-08-26 Motorola, Inc. Method and apparatus for a communications filter
KR20100017667A (en) 2007-06-01 2010-02-16 노보 노르디스크 에이/에스 Stable non-aqueous pharmaceutical compositions
WO2008145728A1 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
EP2178909B1 (en) 2007-08-13 2015-10-21 Novo Nordisk A/S Rapid acting insulin analogues
CN107115523A (en) 2007-11-16 2017-09-01 诺沃—诺迪斯克有限公司 Pharmaceutical composition comprising the peptides of GLP 1 or exenatide and basal insulin peptide
DE102008003568A1 (en) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh New insulin analogs useful for treating diabetes
KR20100111683A (en) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 Novel insulin derivatives having an extremely delayed time-action profile
DE102008025007A1 (en) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Insulin analogs which comprise A chain and B chain with disulfide bonds for use in treatment of diabetes and for cartilage regeneration
DE102008025008A1 (en) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Insulin analogs which comprise A chain and B chain with disulfide bonds for use in treatment of diabetes
DE102008003566A1 (en) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh New insulin analogs useful for treating diabetes
KR20100111682A (en) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 Novel insulin derivatives having an extremely delayed time-action profile
PL219335B1 (en) 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków New slow-release insulin analogues
DE102008051834A1 (en) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Drug, useful e.g. for treating diabetes, preferably type-I or II and for controlling fasting, postprandial and/or postabsorptive plasma glucose concentration, comprises insulin and glucagon-like peptide-1 agonist
LT3228320T (en) 2008-10-17 2020-03-10 Sanofi-Aventis Deutschland Gmbh BETWEEN INSULIN AND GLP-1 AGONIST
DE102009038210A1 (en) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1 agonist
DE102008053048A1 (en) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist
EA020496B1 (en) 2008-11-21 2014-11-28 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Adamantyl benzamide derivative, pharmaceutical composition containing same and use thereof
JP2012532177A (en) * 2009-07-06 2012-12-13 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Thermal and vibration stable insulin formulations
TW201113032A (en) 2009-07-06 2011-04-16 Sanofi Aventis Deutschland Slow-acting insulin preparations
CA2767251C (en) 2009-07-06 2018-08-21 Sanofi-Aventis Deutschland Gmbh Insulin preparations containing methionine
PE20120918A1 (en) 2009-07-31 2012-08-14 Sanofi Aventis Deutschland DEPTH DRUGS THAT INCLUDE AN INSULIN-CONNECTOR CONJUGATE
JP5732053B2 (en) 2009-07-31 2015-06-10 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Sustained insulin composition
PE20121362A1 (en) 2009-11-13 2012-10-17 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION INCLUDING DESPRO36EXENDIN-4 (1-39) -LYS6-NH2, INSULIN GLY (A21) -ARG (B31) -ARG (B32) AND METHIONINE
KR101772372B1 (en) 2009-11-13 2017-08-29 사노피-아벤티스 도이칠란트 게엠베하 Pharmaceutical composition comprising a glp-1 agonist and methionine
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
EP2611458B1 (en) 2010-08-30 2016-09-21 Sanofi-Aventis Deutschland GmbH Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
PH12013501495A1 (en) 2011-01-20 2013-09-16 Zealand Pharma As Combination of acylated glucagon analogues with insulin analogues
WO2012104834A1 (en) 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
CN102219851B (en) 2011-05-09 2012-05-30 甘李药业有限公司 Preparation method for insulin glargine crystals
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP2741765B9 (en) 2011-08-10 2016-09-28 Adocia Injectable solution of at least one type of basal insulin
AU2012300978B2 (en) 2011-08-29 2017-04-27 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013063277A1 (en) 2011-10-25 2013-05-02 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US10350139B2 (en) 2011-10-25 2019-07-16 Corning Incorporated Pharmaceutical glass packaging assuring pharmaceutical sterility
EP2814461B1 (en) 2012-01-09 2019-07-24 Adocia Injectable solution having a ph of 7 and including at least basal insulin, the pi of which is between 5.8 and 8.5, and a substituted co-poly(amino acid)
PL222975B1 (en) 2012-05-23 2016-09-30 Inst Biotechnologii I Antybiotyków Insulin analog or a pharmaceutically tolerated salt thereof, a pharmaceutical composition of prolonged therapeutic use of insulin analog, dosage and method for treatment of diabetes
WO2013173923A1 (en) 2012-05-25 2013-11-28 Diamedica, Inc. Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
PT2854841T (en) 2012-06-04 2017-05-15 Diamedica Inc Human tissue kallikrein 1 glycosylation isoforms
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
FR3001896B1 (en) 2013-02-12 2015-07-03 Adocia PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WHERE THE ISO-ELECTRIC POINT IS BETWEEN 5.8 AND 8.5 AND A HYDROPHOBIC ANIONIC POLYMER
FR3001895B1 (en) 2013-02-12 2015-07-03 Adocia PH7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WHERE THE ISOELECTRIC POINT IS INCLUDED IN 5.8 AND 8.5 AND AN ANIONIC COMPOUND CARRYING CARBOXYLATE LOADS AND HYDROPHOBIC RADICALS
AU2013365945B2 (en) * 2012-12-19 2017-03-02 Wockhardt Limited A stable aqueous composition comprising human insulin or an analogue or derivative thereof
TWI641381B (en) 2013-02-04 2018-11-21 法商賽諾菲公司 Stabilized pharmaceutical formulations of insulin analogs and/or insulin derivatives
MX369511B (en) 2013-04-03 2019-11-11 Sanofi Sa Treatment of diabetes mellitus by long-acting formulations of insulins.
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9713572B2 (en) 2013-04-24 2017-07-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707153B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717649B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707155B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717648B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9895423B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
RU2016132386A (en) 2014-01-09 2018-02-14 Санофи STABILIZED PHARMACEUTICAL COMPOSITIONS WITHOUT GLYCERIN BASED ON INSULIN ANALOGUES AND / OR INSULIN DERIVATIVES
AU2015205624A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
HRP20230470T1 (en) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
CN104688677B (en) * 2015-02-05 2018-02-09 通化东宝药业股份有限公司 A kind of insulin glargine injecta of stabilization and preparation method thereof
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
AR107560A1 (en) 2016-02-24 2018-05-09 Lilly Co Eli COMPOUND THAT DECREASES GLUCOSE IN BLOOD
FR3052072A1 (en) 2016-06-07 2017-12-08 Adocia PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACIDE CARRYING CARBOXYLATE LOADS AND HYDROPHOBIC RADICALS
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
EP4129321B1 (en) 2016-12-05 2025-10-15 Nuritas Limited Compositions comprising peptide wkdeagkplvk
AU2018230478B2 (en) 2017-03-09 2025-01-23 Diamedica Inc. Dosage forms of tissue kallikrein 1
FR3070264A1 (en) 2017-08-24 2019-03-01 Adocia PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN INCLUDING AN INHIBIT OF 5.8 TO 8.5 AND A CO-POLYAMINOACIDE CARBOXYLATE AND HYDROPHOBIC RADICAL CARRIERS
WO2019110625A1 (en) 2017-12-06 2019-06-13 Adocia Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
FR3083089A1 (en) 2018-06-29 2020-01-03 Adocia PH 7 INJECTION SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACID CARRYING CARBOXYLATES AND HYDROPHOBIC RADICALS
FR3083088B1 (en) 2018-06-29 2020-10-02 Adocia SOLUTION FOR INJECTION AT PH 7 INCLUDING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACID CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS
CN111836616B (en) 2017-12-07 2024-01-16 阿道恰公司 Injectable solutions of pH 7 containing at least one basal insulin with a PI between 5.8 and 8.5 and a copolymerized amino acid with a carboxylate charge and a hydrophobic group
EP3740229B1 (en) 2017-12-07 2025-04-09 Adocia Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
MX2020005913A (en) 2017-12-07 2020-10-19 Adocia Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals.
WO2019204206A1 (en) * 2018-04-16 2019-10-24 Chou Danny Hung Chieh Glucose-responsive insulin
WO2019243628A1 (en) 2018-06-22 2019-12-26 Adocia Injectable composition with a ph of 7 comprising a co-polyaminoacid bearing carboxylate charges and hydrophobic radicals and at least one basal insulin having at least a prandial effect and a basal effect
FR3084585B1 (en) 2018-08-03 2020-11-06 Adocia SOLUTION FOR INJECTION AT PH 7 INCLUDING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 AND AN AMPHIPHILIC COMPOUND CARRIER OF HYDROPHOBIC RADICALS
KR102666154B1 (en) 2018-08-08 2024-05-20 주식회사 대웅제약 Long-acting Insulin Analog and Derivatives Thereof
WO2020115334A1 (en) 2018-12-07 2020-06-11 Adocia Method for preparing a stable composition in the form of an injectable aqueous solution
US20200179489A1 (en) 2018-12-07 2020-06-11 Adocia Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol
KR20200080747A (en) 2018-12-27 2020-07-07 주식회사 폴루스 An Enzymatic Conversion Composition for Producing Insulin from Proinsulin and a Method for Producing Insulin from Proinsulin Using the Same
KR20200080748A (en) 2018-12-27 2020-07-07 주식회사 폴루스 A Method for Purifying Proinsulin Using Anion Exchange Chromatography
KR20200082618A (en) 2018-12-31 2020-07-08 주식회사 폴루스 Ramp Tag for Overexpressing Insulin and Method for Producing Insulin Using the Same
WO2020245470A1 (en) 2019-06-07 2020-12-10 Adocia Injectable solution at ph 7 containing at least one basal insulin, the pi of which is between 5.8 and 8.5, liraglutide, and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
TW202434620A (en) 2019-07-31 2024-09-01 美商美國禮來大藥廠 Relaxin analogs and methods of using the same
CN113105536B (en) 2020-09-11 2023-07-18 美药星（南京）制药有限公司 New proinsulin glargine and method for preparing insulin glargine by using same
CN114805610B (en) * 2022-06-23 2022-10-04 北京惠之衡生物科技有限公司 Recombinant genetic engineering bacterium for highly expressing insulin glargine precursor and construction method thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3033127A1 (en) * 1980-09-03 1982-04-08 Hoechst Ag, 6000 Frankfurt NEW INSULIN ANALOG
DE3326472A1 (en) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt NEW INSULIN DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AND PHARMACEUTICAL AGENTS FOR TREATING THE DIABETES MELLITUS
DE3326473A1 (en) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt PHARMACEUTICAL AGENT FOR TREATING THE DIABETES MELLITUS
DE3327709A1 (en) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt INSULIN DERIVATIVE CRYSTAL SUSPENSIONS, METHOD FOR THE PRODUCTION AND USE THEREOF
DK113585D0 (en) * 1985-03-12 1985-03-12 Novo Industri As NEW PEPTIDES
DK347086D0 (en) * 1986-07-21 1986-07-21 Novo Industri As NOVEL PEPTIDES
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
ES2053723T3 (en) * 1987-02-25 1994-08-01 Novo Nordisk As NEW INSULIN DERIVATIVES.

Also Published As

Publication number Publication date
NO894424L (en) 1990-05-09
IL92222A (en) 1999-09-22
US5656722A (en) 1997-08-12
JP2680145B2 (en) 1997-11-19
ES2059676T4 (en) 2012-03-13
EP0368187B1 (en) 1993-09-01
US6100376A (en) 2000-08-08
ATE93868T1 (en) 1993-09-15
JPH02218696A (en) 1990-08-31
AU4441289A (en) 1990-05-17
ZA898456B (en) 1990-06-27
KR900007435A (en) 1990-06-01
DK554789D0 (en) 1989-11-07
HK1006171A1 (en) 1999-02-12
IE893576L (en) 1990-05-08
HU895678D0 (en) 1990-01-28
FI100185B (en) 1997-10-15
DE10075022I1 (en) 2000-10-05
AU621680B2 (en) 1992-03-19
NL300019I2 (en) 2001-02-01
DE58905456D1 (en) 1993-10-07
NO894424D0 (en) 1989-11-07
LU90614I2 (en) 2000-09-26
KR0158197B1 (en) 1998-12-01
IE63338B1 (en) 1995-04-19
NO177963B (en) 1995-09-18
PH30695A (en) 1997-09-16
NO2001023I1 (en) 2001-12-17
PT92220B (en) 1995-07-06
NZ231272A (en) 1992-11-25
ES2059676T3 (en) 1994-11-16
DK173196B1 (en) 2000-03-13
DE10075022I2 (en) 2002-07-04
IL92222A0 (en) 1990-07-26
DE3837825A1 (en) 1990-05-10
HU213018B (en) 1997-01-28
HUT52549A (en) 1990-07-28
FI895259A0 (en) 1989-11-06
NO177963C (en) 1995-12-27
HU210800A9 (en) 1995-07-28
EP0368187A3 (en) 1991-07-03
DK554789A (en) 1990-05-09
EP0368187A2 (en) 1990-05-16
PT92220A (en) 1990-05-31
NL300019I1 (en) 2000-12-01

Similar Documents

Publication Publication Date Title
CA1339044C (en) Insulin derivatives, the use thereof, and a pharmaceutical composition containing them
US4946828A (en) Novel insulin peptides
US5008241A (en) Novel insulin peptides
AU612324B2 (en) Novel peptides and injectable solutions having prolonged insulin action
US6221837B1 (en) Insulin derivatives with increased zinc binding
JP3129722B2 (en) New insulin derivative
US4701440A (en) Insulin derivatives, processes for their preparation and their use, and pharmaceutical agents for the treatment of diabetes mellitus
EP0194864B1 (en) Novel peptides
US4608364A (en) Pharmaceutical agent for the treatment of diabetes mellitus
WO1992000321A1 (en) Novel, protracted insulin analogues
PT93057B (en) PROCESS FOR THE PREPARATION OF INSULIN ANALOGS
IE66564B1 (en) Novel insulin compounds
JPH0691834B2 (en) Method for producing insulin derivative
JP3131215B2 (en) New insulin derivative
HK1006171B (en) Insulin derivatives, their use and a pharmaceutical composition containing same
MXPA97005667A (en) Insulin derivatives with zinc increment

Legal Events

Date Code Title Description
MKEX Expiry

Effective date: 20140401